SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Other Events
Item 8.01. Other Events.

On March 14, 2018, the Registrant issued a press release announcing additional results from the first two cohorts (25mg and 50mg) of Part A of the Registrant’s Phase 2 ACHIEVE clinical trial of patients infected with chronic hepatitis B virus.A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Spring Bank Pharmaceuticals, Inc. Exhibit
EX-99.1 2 sbph-ex991_6.htm EX-99.1 sbph-ex991_6.htm     Exhibit 99.1   Spring Bank Announces Presentation of Combined Inarigivir 25mg and 50mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients   Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA,…
To view the full exhibit click here

About SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH)

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. It also focuses on the use of SB 9200 in other viral diseases, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and latency and hepatitis delta virus (HDV), conducting preclinical research of additional SMNH product candidates or compounds as antiviral therapies and conducting early-stage research programs.